Industry
Biotechnology
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Loading...
Open
9.31
Mkt cap
198M
Volume
46K
High
9.46
P/E Ratio
-1.71
52-wk high
17.80
Low
9.16
Div yield
N/A
52-wk low
8.51
Portfolio Pulse from Benzinga Newsdesk
October 10, 2024 | 11:17 am
Portfolio Pulse from Benzinga Insights
October 09, 2024 | 7:02 pm
Portfolio Pulse from Benzinga Newsdesk
October 09, 2024 | 6:08 pm
Portfolio Pulse from Benzinga Newsdesk
September 27, 2024 | 2:51 pm
Portfolio Pulse from Vandana Singh
September 26, 2024 | 6:00 pm
Portfolio Pulse from Benzinga Newsdesk
September 26, 2024 | 10:02 am
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 4:18 pm
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 10:39 am
Portfolio Pulse from Benzinga Newsdesk
August 05, 2024 | 8:18 pm
Portfolio Pulse from Benzinga Newsdesk
May 07, 2024 | 5:47 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.